FYI... Anavex announced at CTAD, and again at JPM-HC, the results of an astonishingly positive "P3" AD trial that MET ALL ENDPOINTS, where patients actually IMPROVED! I'd call that actual EXECUTION!
It’s hard to make predictions with our history of missed timelines. However it seems to me that the FDA is “motivated” when it comes to Alzheimer’s, as evidenced by its approval of two MABs that had less than stellar results, one of which did not even get approval from their advisory board, and all of this in the setting of dire need for an Alzheimer’s remedy.
News 
Market Data 
Discover 
